Open AccessConjugate serogroup C meningococcal vaccine use extended in the United Kingdom
Author(s) -
Veronique Gibbons
Publication year - 2002
Language(s) - English
Resource type - Journals
ISSN - 9999-1233
DOI - 10.2807/esw.06.02.02002-en
Subject(s) - meningococcal disease , medicine , vaccination , epidemiology , conjugate vaccine , meningococcal vaccine , pediatrics , population , immunization , demography , family medicine , virology , neisseria meningitidis , environmental health , immunology , antigen , biology , bacteria , genetics , sociology
The United Kingdom (UK) Joint Committee on Vaccination and Immunisation (JCVI) has reviewed the epidemiology of group C infection in the population aged 20 years and over and recommended that immunisation should be made available for individuals aged 20-24 years (born after 7 January 1977) (1). The vaccine has already been offered to people who are under 20 years of age (2). This decision comes following successful reduction in disease in the UK of children and young people offered the conjugate meningococcal C vaccine (Men C vaccine).